Cargando…

High-Dose Ascorbate in Combination with Anti-PD1 Checkpoint Inhibition as Treatment Option for Malignant Melanoma

Ascorbate acts as a prooxidant when administered parenterally at high supraphysiological doses, which results in the generation of hydrogen peroxide in dependence on oxygen. Most cancer cells are susceptible to the emerging reactive oxygen species (ROS). Accordingly, we evaluated high-dose ascorbate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burkard, Markus, Niessner, Heike, Leischner, Christian, Piotrowsky, Alban, Renner, Olga, Marongiu, Luigi, Lauer, Ulrich M., Busch, Christian, Sinnberg, Tobias, Venturelli, Sascha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857291/ https://www.ncbi.nlm.nih.gov/pubmed/36672190 http://dx.doi.org/10.3390/cells12020254

Ejemplares similares

Relevant Membrane Transport Proteins as Possible Gatekeepers for Effective Pharmacological Ascorbate Treatment in Cancer
por: Leischner, Christian, et al.
Publicado: (2023)

Therapeutic Efficacy of Pharmacological Ascorbate on Braf Inhibitor Resistant Melanoma Cells In Vitro and In Vivo
por: Niessner, Heike, et al.
Publicado: (2022)

Ex Vivo Evaluation of the Sepsis Triple Therapy High-Dose Vitamin C in Combination with Vitamin B1 and Hydrocortisone in a Human Peripheral Blood Mononuclear Cells (PBMCs) Model
por: Lauer, Annie, et al.
Publicado: (2021)

Epigenetic Impacts of Ascorbate on Human Metastatic Melanoma Cells
por: Venturelli, Sascha, et al.
Publicado: (2014)

Comparative Analysis of the Antitumor Activity of Cis- and Trans-Resveratrol in Human Cancer Cells with Different p53 Status
por: Leischner, Christian, et al.
Publicado: (2021)

Vitamin C Deficiency in Blood Samples of COVID-19 Patients
por: Sinnberg, Tobias, et al.
Publicado: (2022)

Epigenetic activities of flavonoids in the prevention and treatment of cancer
por: Busch, Christian, et al.
Publicado: (2015)

Parenteral high-dose ascorbate - A possible approach for the treatment of glioblastoma (Review)
por: Renner, Olga, et al.
Publicado: (2021)

Minerals and Cancer: Overview of the Possible Diagnostic Value
por: Venturelli, Sascha, et al.
Publicado: (2022)

Nutritional immunology: function of natural killer cells and their modulation by resveratrol for cancer prevention and treatment
por: Leischner, Christian, et al.
Publicado: (2016)

Vitamins as Possible Cancer Biomarkers: Significance and Limitations
por: Venturelli, Sascha, et al.
Publicado: (2021)

Systematic Review of Gossypol/AT-101 in Cancer Clinical Trials
por: Renner, Olga, et al.
Publicado: (2022)

The ROS-induced cytotoxicity of ascorbate is attenuated by hypoxia and HIF-1alpha in the NCI60 cancer cell lines
por: Sinnberg, Tobias, et al.
Publicado: (2014)

Preclinical Efficacy and Toxicity Analysis of the Pan-Histone Deacetylase Inhibitor Gossypol for the Therapy of Colorectal Cancer or Hepatocellular Carcinoma
por: Mayer, Mascha, et al.
Publicado: (2022)

Embryonic bone morphogenetic protein and nodal induce invasion in melanocytes and melanoma cells
por: Sinnberg, Tobias, et al.
Publicado: (2018)

Determination of phage load and administration time in simulated occurrences of antibacterial treatments
por: Plunder, Steffen, et al.
Publicado: (2022)

Potential Protective Protein Components of Cow’s Milk against Certain Tumor Entities
por: Leischner, Christian, et al.
Publicado: (2021)

Dietary Modulation of Bacteriophages as an Additional Player in Inflammation and Cancer
por: Marongiu, Luigi, et al.
Publicado: (2021)

Wnt-signaling enhances neural crest migration of melanoma cells and induces an invasive phenotype
por: Sinnberg, Tobias, et al.
Publicado: (2018)

Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases
por: Chatziioannou, Eftychia, et al.
Publicado: (2023)

Disulfiram as a Therapeutic Agent for Metastatic Malignant Melanoma—Old Myth or New Logos?
por: Meraz-Torres, Francisco, et al.
Publicado: (2020)

Combination of the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus as a new option for epi-virotherapeutic treatment of hepatocellular carcinoma
por: Ruf, Benjamin, et al.
Publicado: (2015)

Individualized Proteogenomics Reveals the Mutational Landscape of Melanoma Patients in Response to Immunotherapy
por: Schmitt, Marisa, et al.
Publicado: (2021)

Resveratrol as a Pan-HDAC Inhibitor Alters the Acetylation Status of Jistone Proteins in Human-Derived Hepatoblastoma Cells
por: Venturelli, Sascha, et al.
Publicado: (2013)

Correction: Resveratrol as a Pan-HDAC Inhibitor Alters the Acetylation Status of Jistone Proteins in Human-Derived Hepatoblastoma Cells
por: Venturelli, Sascha, et al.
Publicado: (2013)

Involvement of HHV-4 (Epstein–Barr Virus) and HHV-5 (Cytomegalovirus) in Inflammatory Bowel Disease and Colorectal Cancer: A Meta-Analysis
por: Marongiu, Luigi, et al.
Publicado: (2022)

Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy
por: Chatziioannou, Eftychia, et al.
Publicado: (2023)

Melanoma cells resistant towards MAPK inhibitors exhibit reduced TAp73 expression mediating enhanced sensitivity to platinum-based drugs
por: Makino, Elena, et al.
Publicado: (2018)

PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction In Vitro and In Vivo
por: Fröhlich, Lisa Marie, et al.
Publicado: (2023)

Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint Inhibition
por: Hassel, Jessica C., et al.
Publicado: (2023)

Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma Patients
por: Hilke, Franz J., et al.
Publicado: (2020)

Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinase
por: Kosnopfel, Corinna, et al.
Publicado: (2017)

An open-label, single-arm, phase II trial of buparlisib in patients with melanoma brain metastases not eligible for surgery or radiosurgery—the BUMPER study
por: Amaral, Teresa, et al.
Publicado: (2020)

Tumour Progression Stage-Dependent Secretion of YB-1 Stimulates Melanoma Cell Migration and Invasion
por: Kosnopfel, Corinna, et al.
Publicado: (2020)

Biological treatment of pediatric sarcomas by combined virotherapy and NK cell therapy
por: Klose, Chihab, et al.
Publicado: (2019)

Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor
por: Escandon, Julia, et al.
Publicado: (2017)

Case Report: Combined CDK4/6 and MEK Inhibition in Refractory CDKN2A and NRAS Mutant Melanoma
por: Forschner, Andrea, et al.
Publicado: (2021)

Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy
por: Bochem, Jonas, et al.
Publicado: (2021)

MDM2, MDM4 and EGFR Amplifications and Hyperprogression in Metastatic Acral and Mucosal Melanoma
por: Forschner, Andrea, et al.
Publicado: (2020)

Anti‐PD‐1 antibodies in metastatic uveal melanoma: a treatment option?
por: Bender, Carolin, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_u3rho6e84ebdltc4205e2n0n5v